Fecal immunohistochemical test (FIT) as screening tool for colorectal cancer (CRC) among asymptomatic healthy adults, aged 45 years old and above

HTA Council Recommendation (as of 26 February 2025) The HTA Council recommends qualitative Fecal immunohistochemical test (FIT) as an annual screening test for colorectal cancer (CRC) for apparently healthy adults aged 50 years and above for financing of DOH and/or PhilHealth (See below for more details). Relevant Information Evidence and Relevant Documents Assessment History Back continue reading : Fecal immunohistochemical test (FIT) as screening tool for colorectal cancer (CRC) among asymptomatic healthy adults, aged 45 years old and above

CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old

Date of SOH Approval: 10 October 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of CoronaVac COVID-19 Vaccine for children continue reading : CoronaVac COVID-19 Vaccine for Children 6 to 17 Years Old

Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old

Date of SOH Approval: 26 August 2022 Pursuant to the role of the Health Technology Assessment Council (HTAC) to develop coverage recommendations particularly in the selection and financing of COVID-19 vaccines using the Evaluation Framework set by the HTAC, this report presents all currently available evidence considered in the assessment of Second Booster of COVID-19 vaccines continue reading : Second Booster of COVID-19 Vaccines for the Prevention of COVID-19 Among Individuals Aged 50 Years Old and Older and Individuals with Comorbidities Aged 18 to 49 Years Old

Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)

The Secretary of Health (SOH) approved the HTAC recommendation on April 21 to finance a fourth dose of COVID-19 Vaccines AstraZeneca, CoronaVac, Moderna, Pfizer-BioNTech, and Sinopharm among the immunocompromised population (ICPs) ages 18 years old and above given at least 3 months after the third dose, and include these vaccines in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP).  While continue reading : Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)